A closer look at the evidence, the GLA mechanism, doses studied, and the interactions that matter.

Evening primrose oil for perimenopause: what the evidence says

Hot flashes can wreck a night. If a supplement aisle promises a softer alternative to hormone therapy, evening primrose oil (EPO) sounds plausible. The catch is that “plausible” is not the same as proven.

Here is the short version: EPO has been studied for menopausal hot flashes, but results are mixed. The best-reviewed evidence does not support treating it as a reliable hot-flash solution.

This is a label-and-evidence read, not medical advice. Perimenopause is also different from postmenopause, and much of the trial evidence below involved postmenopausal women.

What evening primrose oil is made of

EPO comes from the seeds of Oenothera biennis. It is an omega-6 fatty-acid oil, rich in linoleic acid and gamma-linolenic acid, or GLA. A 2024 systematic review described commercial EPO as roughly 60% to 80% linoleic acid and 8% to 14% GLA, though the exact profile varies by product and processing.

GLA is the part most often attached to a proposed mechanism. The body can convert GLA into DGLA and then into prostaglandin E1, signaling molecules involved in inflammation and normal physiological processes. That pathway is real. It is not direct proof that swallowing EPO changes a hot flash.

A 1994 BMJ randomized, double-blind trial found no benefit over placebo for menopausal flushing. It used 2,000 mg daily for six months; only 35 of 56 participants completed it.

Does it help hot flashes?

The honest answer is: sometimes, maybe, for some measures, in some studies. Not consistently enough to call it a dependable solution.

A 2024 systematic review and meta-analysis found that hot-flash severity was lower with EPO when treatment lasted less than six months, but it found no significant difference in frequency or duration versus placebo. The authors said the evidence was insufficient for firm conclusions. Mild nausea and headache were reported.

A newer meta-analysis of six randomized trials, published in 2025, reached a similar nuanced result. Across 450 women, EPO did not produce a statistically significant reduction in daily hot-flash frequency or intensity. It did find a statistically significant reduction in hot-flash duration, but the evidence was rated moderate to low and the trials were heterogeneous.

So “EPO reduces hot flashes” is too broad. Studies have produced mixed findings, with some signal around duration, and no dependable effect on frequency or intensity.

Dose matters too. The studies are not a shopping list for a dose. Trials have used different amounts and durations, including 500 mg daily for six weeks, 1,000 mg twice daily for eight weeks, and 2,000 mg daily for six months. A capsule’s milligrams are not the same as its standardized GLA amount, so check the label rather than copying a study dose blindly.

Why is EPO in Ritual’s perimenopause formula?

Ritual’s launch material for Perimenopause Health says its evening primrose oil is included “to help support the absorption of DIM.” The same company says DIM helps support healthy estrogen metabolism. Those are two separate claims.

The absorption claim is about a fatty source helping the absorption of fat-soluble DIM. It does not mean EPO has been shown to improve hot flashes, balance hormones, or replace medical care. Ritual also markets the overall product with structure-shiffling claims and a disclaimer that the statements have not been evaluated by the Food and Drug Administration. See our Ritual Perimenopause Health ingredient review for the label-level read.

That distinction matters because “supports absorption of X” and “helps symptom Y” require different evidence. Do not borrow the confidence from one claim and attach it to the other.

Safety and interactions

NCCIH says oral EPO is probably safe for most adults for short periods, but long-term safety is not established. Common side effects include abdominal pain, nausea, and diarrhea. Headache and dizziness can also occur.

The interaction that deserves a real pause is blood thinning. Memorial Sloan Kettering notes that EPO may have additive effects with anticoagulants and antiplatelet drugs. NCCIH specifically warns that it may increase bleeding risk in people taking warfarin. Anyone using warfarin, apixaban, rivaroxaban, aspirin, clopidogrel, or another blood-thinning medicine should ask a pharmacist or prescriber before adding EPO. Do not stop a prescription on your own.

EPO can also interact with other medicines. NCCIH advises talking with a healthcare provider before using it if you take any medication. A history of hormone-sensitive cancer, unusual bleeding, a planned surgery, or another health concern deserves an individualized conversation rather than a shelf experiment.

For a broader symptom comparison, see our supplement guide for hot flashes. The short version is that symptom tracking, nonhormonal prescription options, and medical care can be discussed without pretending a capsule has a guaranteed answer.

The buy-or-skip read

EPO is not automatically a bad supplement. It is a weakly fitting one for the promise many people want it to carry. If you are choosing it specifically for hot flashes, you should know that the evidence is mixed and that the strongest placebo-controlled trial found no benefit. If you are looking at a combination product, check whether EPO is there for DIM absorption, not because the formula has proven symptom relief.

And if hot flashes are frequent, disrupting sleep, or changing your day, that is enough information to take to a clinician. A supplement does not need to be dangerous to be a poor fit. Sometimes the honest answer is simply: the receipt does not show enough benefit to justify the price or the risk.